Video
Urology Times 50 Innovations Series: PSA testing
Author(s):
"The fact that it was a simple blood test, it was absolutely objective, and it was…non-invasive…made it very attractive," says William J. Catalona, MD.
Video Player is loading.
As part of the Urology Times' 50th Anniversary Innovation Celebration, William J. Catalona, MD, discusses how prostate-specific antigen (PSA) testing has greatly impacted the field of urology over the past 50 years. Catalona is a professor of urology at Northwestern University in Chicago, Illinois.
Related Videos
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Related Content
